Published in Neoplasia on December 01, 2007
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res (2010) 1.05
Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys (2011) 1.04
Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed (2010) 1.03
Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. ACS Chem Biol (2010) 1.01
DNA methyltransferase inhibition induces mouse embryonic stem cell differentiation into endothelial cells. Exp Cell Res (2009) 0.90
MRI of metastasis-permissive microenvironments. Future Oncol (2011) 0.78
The War on Cancer rages on. Neoplasia (2009) 0.75
Enzymatically Regulated Peptide Pairing and Catalysis for the Bioanalysis of Extracellular Prometastatic Activities of Functionally Linked Enzymes. Sci Rep (2016) 0.75
Neoplasia: the second decade. Neoplasia (2008) 0.75
Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging. Front Oncol (2017) 0.75
The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med (1962) 23.03
On respiratory impairment in cancer cells. Science (1956) 14.07
Putting tumours in context. Nat Rev Cancer (2001) 12.37
The microenvironment of the tumour-host interface. Nature (2001) 9.17
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev (2006) 7.92
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature (1986) 4.57
Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res (2004) 4.54
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) (2004) 3.79
The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci (2000) 3.70
Mechanisms of cancer cell invasion. Curr Opin Genet Dev (2005) 3.47
Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res (2003) 2.66
The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch (2003) 2.58
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis (2003) 1.94
Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia (2001) 1.56
Mechanisms of cell survival in hypoxia and hypothermia. J Exp Biol (2001) 1.54
Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med (2003) 1.54
Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol (2004) 1.52
Control of fatty acid metabolism in ischemic and hypoxic hearts. J Biol Chem (1978) 1.45
Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol (2005) 1.44
Ions and energy in mammalian brain. Prog Neurobiol (1994) 1.40
Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer (1999) 1.34
Extracellular matrix composition and hypoxia regulate the expression of HLA-G and integrins in a human trophoblast cell line. Biol Reprod (2000) 1.24
Role of focal adhesion kinase and phosphatidylinositol 3'-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells. Cancer Res (2006) 1.22
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol (2005) 1.20
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis (1998) 1.15
Evolution of the coordinate regulation of glycolytic enzyme genes by hypoxia. J Exp Biol (2003) 1.15
Human microvessel endothelial cells: isolation, culture and characterization. In Vitro Cell Dev Biol Anim (1993) 1.14
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate (1997) 1.11
Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood (1998) 1.09
Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia (2007) 1.02
Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber. Neoplasia (2000) 1.01
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis (2002) 1.01
Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion. Br J Cancer (2001) 1.00
Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost (1997) 1.00
Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol (2004) 1.00
Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat Res (2005) 0.99
Choline phospholipids: signal transduction and carcinogenesis. FASEB J (1993) 0.98
Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res (2004) 0.96
Fast control of DNA replication in response to hypoxia and to inhibited protein synthesis in CCRF-CEM and HeLa cells. Biol Chem (1999) 0.96
Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res (1996) 0.96
Membrane invasion culture system (MICS). Med Instrum (1984) 0.89
Involvement of dipeptidyl peptidase IV in extravillous trophoblast invasion and differentiation. J Clin Endocrinol Metab (2002) 0.84
Noninvasive MRI of endothelial cell response to human breast cancer cells. Neoplasia (2006) 0.83
Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. Cancer Lett (2005) 0.83
Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells. Mol Imaging (2003) 0.82
Inhibition of endothelial cell differentiation on a glycosylated reconstituted basement membrane complex. Exp Cell Res (1996) 0.80
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
A microenvironmental model of carcinogenesis. Nat Rev Cancer (2008) 4.40
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res (2006) 3.90
Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res (2009) 3.40
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Adaptive therapy. Cancer Res (2009) 2.81
Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med (2013) 2.74
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res (2005) 2.32
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
Tumor pH and its measurement. J Nucl Med (2010) 2.08
Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05
Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med (2003) 2.05
High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med (2006) 1.97
Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol (2007) 1.94
The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res (2009) 1.92
Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets (2004) 1.86
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84
Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res (2009) 1.84
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med (2003) 1.76
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
Imaging pH and metastasis. NMR Biomed (2011) 1.67
Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem (2004) 1.66
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia (2003) 1.63
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol (2006) 1.59
Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg Med Chem Lett (2004) 1.58
Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol (2003) 1.57
Quantitative imaging in cancer evolution and ecology. Radiology (2013) 1.55
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther (2005) 1.54
Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia (2005) 1.54
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res (2008) 1.52
Lateral phase separation in lipid-coated microbubbles. Langmuir (2006) 1.52
Of cancer and cave fish. Nat Rev Cancer (2011) 1.50
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (2005) 1.45
Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis (2008) 1.44
Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". Int J Cancer (2014) 1.44
Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm (2011) 1.42
Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res (2006) 1.41
Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents. NMR Biomed (2011) 1.40
Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem (2005) 1.38
Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol (2003) 1.38
Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res (2012) 1.38
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36
Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One (2011) 1.36
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia (2002) 1.32
Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31
Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol (2012) 1.28
Self-assembled three dimensional radio frequency (RF) shielded containers for cell encapsulation. Biomed Microdevices (2005) 1.28
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res (2003) 1.26
Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One (2012) 1.25
Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor. Anal Biochem (2005) 1.25
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia (2008) 1.23
Optimization of SABRE for polarization of the tuberculosis drugs pyrazinamide and isoniazid. J Magn Reson (2013) 1.23
Thermostability of firefly luciferases affects efficiency of detection by in vivo bioluminescence. Mol Imaging (2004) 1.23
A stimulus-responsive contrast agent for ultrasound molecular imaging. Biomaterials (2007) 1.22
Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol (2011) 1.22
Reduction of metastasis using a non-volatile buffer. Clin Exp Metastasis (2011) 1.21
Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21
Evolutionary dynamics of cancer prevention. Nat Rev Cancer (2010) 1.20
Rigid linkers for bioactive peptides. Bioconjug Chem (2006) 1.19
Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets (2003) 1.19
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med (2013) 1.19
Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res (2012) 1.19
Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol (2004) 1.17
The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res (2005) 1.17
DNA and polylysine adsorption and multilayer construction onto cationic lipid-coated microbubbles. Langmuir (2007) 1.16
Gold nanorods targeted to delta opioid receptor: plasmon-resonant contrast and photothermal agents. Mol Imaging (2008) 1.15
Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 1.15
Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med (2006) 1.14
MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed (2007) 1.14
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med (2008) 1.13
Lanthanide-based luminescent assays for ligand-receptor interactions. Life Sci (2005) 1.13
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
Animal anaesthesia for in vivo magnetic resonance. NMR Biomed (2003) 1.11